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ABSTRACT
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support of the tissue scaffold, where the scaffold body
comprises scaffold body components bonded to each other
and made from component materials comprising about 40 to
about 90 wt % BO, and two or more other oxides, wherein
the scaffold body has a porosity between about 15 and about
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FIG. 2 is a photograph of a cross section of a scaffold of

SCAFFOLD FOR TISSUE REGENERATION
IN MAMMALS

the invention.

FIGS. 3A, 3B, 4A, 4B, 4C, and 4D are SEM micrographs
of cross sections of a scaffold of the invention.

REFERENCE TO RELATED APPLICATION

FIGS. 5, 6, 7, 8A, 8B, 8C, and 8D are optical micrographs
of cross sections of a scaffold of the invention subjected to
histological staining.

This is a continuation of U.S. Ser. No. 12/504,489 filed
Jul. 16, 2009 and issued Jul. 9, 2013 as U.S. Pat. No.
8,481,066.

FIGS. 9A, 9B, 9C, 9D, 10A, 10B, 10C, and 10D are

FIELD OF THE INVENTION

10

This invention relates to a biocompatible scaffold for
implantation into mammals to facilitate tissue repair, regen
eration, and proliferation.

15

BACKGROUND OF THE INVENTION

optical micrographs of cross sections of a scaffold employ
ing prior art scaffold materials Subjected to histological
staining.
FIG. 11 is an x-ray diffraction profile of a scaffold
discussed in a below Example.
FIGS. 12A, 12B, 12C, 12D, 12E, and 12F are photo
graphs of Scaffolds according to an Example.
FIGS. 13A, 13B, 13C, 13D, 13E, 13F, 14A, 14B, 14C,

14D, 14E, and 14F are photographs of scaffolds of FIGS.
12A, 12B, 12C, 12D, 12E, and 12F after implantation.

Day et al. U.S. Pat. No. 6,709,744 describes bioactive
materials for implantation which include borate-based glass
or ceramic materials containing
NaO 20 to 35 wt %

DESCRIPTION OF PREFERRED
EMBODIMENTS

CaO 20 to 35 wt %

POs 0 to 10 wt %
BO, 30 to 50 wt %
A specific example is a glass containing about 22.9 wt %
NaO, about 22.9 wt % CaO, about 5.6 wt % P.O.s, and
about 48.6 wt % B.O. These materials contain a high CaO
concentration to facilitate the formation of hydroxyapatite
when exposed to phosphorus-containing fluids in vivo or
prior to implantation. These materials are in the form of
loose particulates which are loosely packed, for example in
a glass capillary tube for release into a host. Liang et al.,
Bioactive Borate Glass Scaffold for Bone Tissue Engineer
ing, J. Non-Crystalline Solids 354 (2008), p. 1690-96; and

25

8.481,066, the entire disclosure of which is incorporated by
reference.
30

35

Yao et al., In Vitro Bioactive Characteristics of Borate

Based Glasses with Controllable Degradation Behavior, J.
Am. Cer. Soc. 90 (2007), p. 303-306 also disclose borate
based glasses formulated with high CaO to facilitate such
formation of hydroxyapatite. For example, the OB, 1B, 2B,
and 3B glasses described by Yao et al. contain 0, 17.7, 35.4,

40

and 53 wt.% borate.
SUMMARY OF THE INVENTION
45

Briefly, therefore, the invention is directed to a three
dimensional scaffold with interconnected pores for repair of
tissue comprising a scaffold body for structural Support of
the tissue scaffold, where the scaffold body comprises scaf
fold body components bonded to each other to define the
scaffold body and provide a scaffold body compressive
strength of greater than 0.4 MPa, wherein the scaffold body
components are of a component material comprising about
40 to about 90 wt % BO, and two or more other oxides
from among those discussed hereinbelow, wherein the scaf
fold body has a porosity between about 15 and about 90 vol

This is a continuation of U.S. Ser. No. 12/504,489 filed
Jul. 16, 2009 and issued Jul. 9, 2013 as U.S. Pat. No.

50

The tissue scaffold of the present invention in one aspect
employs structural components in the form of one or more
of fibers, hollow fibers, tubes, ribbons, solid spheres, hollow
spheres, particles, and combinations thereof. The compo
nents are formed from a component material which is
borate-based and which is glass, crystalline, or a combina
tion of glass and crystalline, and which may or may not
contain CaO for facilitating the formation of hydroxyapatite
or other calcium phosphate compounds.
The structural scaffold body components are bonded to
each other, typically by heating, to define the scaffold body
and provide a scaffold body compressive strength of greater
than 0.4 MPa. The desired compressive strength is selected
so that the components are in no sense free flowing, and so
that the scaffold body can be handled without disintegrating
into the individual body components. The desired compres
sive strength is also selected to provide the strength that is
required to remain integral after implantation, whether for
repair of a load-bearing body part or non-load-bearing part,
or one Subject to impact or significant movement. In some
preferred embodiments, the compressive strength of the
scaffold body is at least about 5 MPa, while in other
embodiments where greater rigidity is required, the com
pressive strength is at least about 20 MPa, such as between
about 20 and about 200 MPa.

In a preferred embodiment the material contains the
following, with all percentages herein being by weight,
55

unless stated otherwise:

%.

Other objects and features of the invention are in part
apparent and in part pointed out hereinafter.
60

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A is a photograph of glass fibers employed in
preparing a scaffold of the invention.
FIG. 1B is a photograph of a mold used in preparing a
scaffold of the invention.

FIG. 1C is a photograph of a scaffold of the invention.

65

B2O3
Na2O
Li2O
KO
Rb2O

40 to
O to
O to
O to
O to

90
25
25
25
25

CaO

O to 40

MgO

O to 25

SO
BaO

O to 40
O to SO

Li2O + NaO + K2O + Rb2O

O to SO
cumulative

US 9,561,250 B2
4
90 wt % B.O. Borate glasses have several important
advantages for biological use Such as their ease of prepara
tion, ability to be made into glass particulates, microspheres
or fibers at relatively low temperatures without crystalliza
tion, and, particularly, their biocompatibility and high
degree of bioactivity. The borate glasses disclosed herein,
compared to silicate glasses, have significantly faster reac
tion rates, lower melting temperatures, resistance to crystal

3
-continued
MgO + SrO + BaO + CaO

O to SO
cumulative
O to 10
O to 18
O to 3
O to 4
O to 10
cumulative.

POs
SiO2
Al2O3
F
transition metal elements

10

The concentrations of KO and MgO in certain of these
embodiments are each from about 1 to about 25 wt %. In

most embodiments, the one or more of LiO, NaO, K2O,
and RbC) is present in a cumulative concentration between
about 1 and about 50 wt % and the one or more of MgO,
SrO, BaO, and CaO is present in a cumulative concentration

15

between about 1 and about 50 wt %,

In most embodiments the scaffold consists only or essen
tially of components meeting these compositional require
ments or other narrower descriptions herein. But generally
speaking, for some embodiments other materials not meet
ing these descriptions may be incorporated into the scaf
folds.

Exemplary scaffold component materials within this
description contain, by weight 96:

25

TABLE I

Wt. 90 Composition of Borate Glasses
A.
B
C
D
E
F
G
H
I
J

B.O.

Na2O

K-O

53
70.4
63.8
49.3
78.5
70
78.7
78.7
76
59

6

12

Li2O

CaO

10.3

2O
19.3
17.2

19
14.6

BaO

30

MgO

POs

5

4

36.1
11.5
1O.O
11.3
11.3
11
8

10
1O.O

35

1O.O
1O.O
1O.O
13
33

It can therefore be appreciated that the scaffolds include
component materials containing 40 to 90 wt % BO or 50
to 90 wt % BO, or even the narrower BO ranges
described herein, in combination with 1 to 25 wt % NaO.
1 to 25% K2O, 1 to 40 wt % CaO, 1 to 25 wt % MgO, and
1 to 10 wt % POs. Or the component materials may contain
40 to 90 wt % BO, 1 to 25 wt % LiO, and 1 to 40 wt %
CaO. Or they may contain 40 to 90 wt % BO, 1 to 25 wt
% Na2O, and 1 to 40 wt % CaO. Or they may contain 40 to
90 wt % BO, 1 to 25 wt % NaO, and 1 to 40 wt % BaO.
Or they may contain 40 to 90 wt % BO, 1 to 25 wt % LiO,
and 1 to 25 wt % MgO. Or they may contain 40 to 90 wt %
BO, 1 to 25 wt % LiO, and 1 to 40 wt % BaC). While the
scaffold component materials herein are described as con
taining various oxides by weight '%, those skilled in the art
understand that in the final glass or glass/crystalline com
position, the individual oxygen, barium, boronetc. elements
are largely dissociated, and the specific oxides, e.g., B.O.
are not separately identifiable or even necessarily separately
present. Nonetheless, it is conventional in the art to refer to
the final composition as containing a given "% of the indi
vidual oxides, so that is done here. So from this perspective,
the compositions herein are on an equivalent basis.
The scaffold component materials of the invention are
borate-based in that they contain between about 40 and
about 90 wt % BO, such as between about 50 and about

40

45

50

55

lization, and in certain instances the absence of silica which

only slowly degrades in the body. So while certain embodi
ments employ up to about 18 wt % SiO, in many other
preferred embodiments herein, the scaffolds are silicate-free,
containing less than 0.1 wt % Silicate or even no silicate.
Borate glasses form hollow fibers upon reaction in vivo,
while silicate glasses do not; and they facilitate angiogenesis
in vivo. The borate glasses described herein also release
boron in-vivo as they react with the body fluids, and since
boron has been reported to promote bone density, and to
Support the biological function of Mg and Ca, which are
components of natural bone, borate glasses can provide an
added function in bone repair/regeneration.
The self-bonded scaffolds of borate glass fibers, described
in the examples and figures herein, reacted rapidly with body
fluids such that they lose up to 60% of their initial weight
and are completely impregnated with vascularized soft tis
sue in less than 4 weeks. The higher in vivo reaction rate of
the borate glasses, which can be approximated by calcula
tion as in below Example 9, substantially decreases the time
the artificial material is in the body, and can promote faster
complete healing of the defect. In preliminary in vivo
experiments, borate glass appears to produce a significantly
milder immune response than commercial bioactive silicate
glass compositions.
There is one embodiment which has specific preference in
certain applications and wherein the concentration of Ca
(elemental or in CaO or other compounds) in the scaffold
body component material is controlled to less than about 5
wt %. Certain preferred embodiments strictly control the Ca
concentration to less than about 0.5 wt %, such as to less

than 0.2 wt %, and even to less than 0.1 wt %. The advantage
in this embodiment to strictly controlling Ca concentration
is the avoidance of the formation of apatite and related
compounds upon exposure to physiological phosphorus
containing fluids. Such apatite compounds include hydroxy
apatite Cas (PO4)(OH), fluoroapatite Cas(PO).F. and
amorphous calcium phosphate (ACP). In certain applica
tions it is advantageous to avoid the formation of Ca-apatite
compounds because they have a relatively lower radiopacity
than do, for example, analogous Ba compounds. In certain
situations it is advantageous to avoid Ca-apatite compounds
in order to form compounds which degrade more rapidly, or
perhaps even more slowly. It can also be advantageous to
avoid Ca for purposes of controlling melt characteristics,
Such as Viscosity, melting temperature, and/or crystallization
tendency.
The scaffold of the invention which is constructed from

60

65

Ca-free material in one embodiment preferably contains
between about 40 and about 90 wt % BO with the
remainder being selected from alkali oxides and alkaline
earth oxides, and other optional constituents listed below.
For example, this scaffold material contains, by weight %:
B2O3
Na2O
Li2O

40 to 90
O to 25
O to 25

US 9,561,250 B2
6
and combinations thereof is in the range of 1 to about 50 wt
%, such as in the range of 1 to 30 wt %, or even about 8 to

5
-continued
KO
Rb2O
MgO

O to 25
O to 25
O to 25

SO
BaO

O to 40
O to 25

Li2O + NaO + K2O + Rb2O

25 wt %. Certain of these embodiments contain two or more

such alkaline earth oxides in a range of 1 to 45 wt %
cumulatively, such as in the range of 5 to 25 wt %.
These scaffold embodiments employing scaffold material
with mixed alkali oxide contents contain BO, from about

O to SO
cumulative

MgO + SrO + BaO

40 to about 90 wt %. Certain of these embodiments consist

O to SO
cumulative
O to 10
O to 18
O to 3
O to 4
O to 10
cumulative.

POs
SiO,
Al2O3
F
transition metal elements

10

40 to about 90 wt %, two or more alkali oxides selected from
15

Certain of these embodiments contain low levels of Ca, as

described above; while others are substantially Ca-free and
contain essentially no or less than 0.1 wt % Ca.
In one preferred embodiment, the material contains
between about 50 and about 80 wt % B.O.; between about
5 and about 20 wt % alkali oxide component selected from
the group consisting of LiO, NaO, K2O, Rb2O, and

90 wt %, two or more mixed alkali oxides selected from the
cumulative wt % between 5 and 25%, and two or more from

among MgO, SrO. BaO, and CaO in a cumulative wt %
between 8 and 25%. Other embodiments optionally include
one or more of POs, SiO, Al2O, F, and transition metal
elements.

25

embodiments. In some embodiments the scaffold material

consists essentially of between about 50 and about 80 wt %
B.O.; between about 5 and about 20 wt % alkali oxide
component selected from the group consisting of LiO,
NaO, KO, Rb O, and combinations thereof; and between
about 5 and about 40 wt % alkaline earth component
selected from the group consisting of MgO, SrO, BaO, and

30

35

Exemplary borate-based scaffold component Ca-free
materials contain, by weight 96:
40

Wt. 90 Composition of Ca-Free Borate Glasses
I
II
III
IV
V
VI
VII

NaO

49.3
78.7
78.7
76
59
45
70

14.6

Li2O

MgO

11.3
11.3
11
8
7
10

10

BaO
36.1

10

10
13
33
48
10

optionally two or more Such oxides cumulatively in this
range. They also optionally employ alkaline earth oxides
from group consisting of MgO, SrO. BaO, CaO, and com
binations thereof in the range of about 1 to about 50 wt %,
such as in the range of 1 to 30 wt %, or even about 8 to 25
wt %, and even two or more such oxides cumulatively in this
range. Certain of these embodiments consist essentially of
these components. Such as compositions II, III, IV, and VII
in Table II; while other embodiments optionally include one
or more of POs, SiO, Al-O. F. and transition metal
elements.

45

In the foregoing described mixed-alkali and high-borate
embodiments, the Ca concentration may be strictly con
trolled to less than about 5 wt %, including to less than 0.5
wt %, such as to less than 0.2 wt % or less than 0.1 wt % to

50

In certain embodiments of the invention, the scaffold

component materials are selected to include at least two of
the alkali oxides LiO, NaO, KO, and/or RbO in a
cumulative concentration of between about 5 and about 25

The invention includes scaffold embodiments employing
scaffold material with an especially high BO composition,
namely, from about 60 to about 90 wt %, preferably from
about 60 to about 82 wt %, still more preferably from about
70 to about 80 wt %. These embodiments employ an alkali
oxide selected from the group consisting of LiO, NaO.
KO, Rb2O, and combinations thereof cumulatively from
about 1 to about 50 wt %, such as from about 5 to about 25
wt %, and even from about 8 to about 20 wt %; and even

combinations thereof.

TABLE II

the group consisting of LiO, NaO, K2O, and RbC), and
two or more alkaline earth oxides from the group consisting
of MgO, SrO. BaO, and CaO. For example, composition A
in Table I consists essentially of BOs from about 40 to about
group consisting of LiO, Na2O, K2O, and RbC) in a

combinations thereof, and between about 5 and about 40%

alkaline earth component selected from the group consisting
of MgO, SrO. BaO, and combinations thereof. While POs,
SiO, Al2O, F, and transition metal elements. Lanthanides
are specifically and strictly excluded from certain preferred

B.O.

essentially of BO, from about 40 to about 90 wt %, mixed
alkali oxides selected from the group consisting of LiO,
NaO, K2O, and RbC), and one of MgO, SrO, BaO, or CaO.
Other embodiments consist essentially of BOs from about
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avoid the formation of Ca compounds. Alternatively, there
are embodiments containing two or more alkali oxides
which also contain CaO in an amount up to about 40 wt %
to facilitate the formation of hydroxyapatite, other calcium
phosphate compounds, or amorphous calcium phosphate.
Another specific embodiment of the invention contains
one or more elements selected from the group consisting of

wt %, such as between about 8 and 20 wt %. It has been

Zn, Cu, Fe, Mn, Si, F, Sr., Ni, Mo, and Se, in an amount

discovered to be advantageous to include two or more Such
alkali compounds in order to reduce the tendency for crys
tallization, which ultimately improves the workability and
manufacturability of the glasses to make Scaffolds. Using
more than one type of alkali (i.e., mixed alkali) can reduce
the cost of a glass, modify its reaction rate with body fluids,
and provide additional elements beneficial to bone growth
and regeneration.

between about 0.01 and 10 wt % per element and cumula
tively less than 25 wt %. These are provided to the glass in
the form of oxides or other compounds. These various
optional elemental additions provide specific functions and
advantages for specific applications. One or more of these
elements within these ranges may also optionally be
included in the previously described embodiments, i.e., the

A further feature of certain embodiments of the invention
is that the cumulative concentration of the alkaline earth

oxides from the group consisting of MgO, SrO, BaO, CaO.

60

embodiment in which the cumulative concentration of the
65

various alkali oxides from the group consisting of Li2O,
NaO, K2O, Rb2O, and combinations thereof is maintained
in the range of about 0 to about 30 wt %, and the embodi

US 9,561,250 B2
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conditions of depressed growth, abnormalities associated
with the skull, long bone, and overall bone architecture.
Silicon in bone is primarily located in osteoblast mitochon
dria, the cells responsible for forming new connective tissue

7
ment in which the Ca concentration is strictly controlled to
less than about 0.2 wt %, such as to less than 0.1 wt %. The

trace elements may be incorporated as oxides into the
scaffold materials.

Nickel increases endothelial cell motility, which is an
important step to angiogenesis. Cell motility is the migration
of cells due to a stimulant, in this case the presence of the

5

trace element Ni.

Selenium functions as an antioxidant that is capable of
protecting the body against oxidative stress associated with
the natural immune response of creating excess reactive
oxygen species to kill and destroy microbial pathogens and
viruses. Essentially, the selenium is keeping the reactive
oxygen species in check so that there is no negative response
to the body cells and tissues. Animals with deficiencies in
Selenium have shown impaired immune responses that
resulted in phagocytic neutrophils and macrophages unable
to combat antigens. Selenium Supplementation in animal

10

15

25

30

35
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0.05 and about 5 wt %, such as between about 0.1 and about

2.5 wt %. There are preferred embodiments employing from
about 1 wt % to about 2 wt % copper compound, such as
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from about 1 wt % to about 2 wt % CuO.

Iron acts as a signal for the enzymes that produce colla
gen. Removal or absence of Fe will basically turn off the
enzymes.

Manganese acts as a cofactor for glycosyltransferases,
which is the transfer of Sugar from a nucleotide-diphosphate
Sugar to an acceptor molecule. Manganese is essential for
several formation stages of glycosaminoglycan chondroitin
Sulphate. Chondroitin Sulphate is a major constituent in
connective tissues such as blood vessels, bone, and cartilage.
Silicon is essential for normal bone matrix formation and

possibly bone mineralization. Deficiencies of Si can cause

Fluorine can affect hydroxyapatite crystallization by
replacing a hydroxyl ion and improving the stability of the
crystals. It is important to note that F must be incorporated
into bone as it is forming, because it will not diffuse into
formed bone. The skeletal system responds to F by increas
ing the number of osteoblast (bone forming cells), hence
forming more bone. The increase in osteocytes is due to the
F increasing osteoprogenitor cell proliferation by increasing
the activity of the bone cell mitogens (proteins that promote
cell division).
Strontium is believed to have metabolic effects on bone
formation. Strontium has been shown in several animal

models has been shown to increase several immune func

tions, including, but not limited to; neutrophil migration,
T-cell proliferation and function, cytotoxic T-cell activity,
T-cell response, lymphokine-activated killer cell activity,
and vaccine-induced immunity to malaria and polio. Most of
these immune functions are natural to the wound healing
process and increasing or promoting these cellular activities
would promote wound healing. Therefore incorporating Se
in the components of the invention promotes and stimulates
natural biological immune responses required for soft tissue
healing and regeneration.
Zinc is a cofactor required for the formation of alkaline
phosphatase, an enzyme found in bone tissue. The greatest
amount of Zn in bone is located in the layer of osteoid prior
to calcification. Zinc is a cofactor with Mg, therefore both
must be present to gain the benefits of either. Zinc has been
found to incorporate into hydroxyapatite, and when F is also
present, the Zn and Zn-F complex may improve the
crystallinity of the apatite.
Copper, when deficient, inhibits bone growth and
increases the changes associated with osteoporosis. Copper
does not become incorporated into the HA, but is used by the
osteoblast and osteoclast cells. When there is a deficiency,
both osteoblast (bone formers) and osteoclast (bone resorb
ers) decrease in activity. Osteoporosis is triggered by the
greater relative reduction of osteoblast compared to the
osteoclast. Copper has also been shown to have an effect on
endothelial cell migration which can be useful for blood
vessel formation and has potential importance for both hard
and Soft tissue regeneration. The Source of Cu to the glass
may be a copper oxide such as CuO or CuO or other copper
compounds such as copper nitrate or copper Sulfate, for
example. In one embodiment the copper compound is incor
porated into the glass in a concentration of between about

matrix material.
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models to reduce osteoclast (bone resorbing cells) activity
without any toxic effect on the osteoclast cells. Increased
replication of pre-osteoblastic cells has been seen with
addition of Sr and led to an increase in bone matrix synthe
sis. Strontium has been considered as a component for future
treatment of osteoporosis.
Accordingly, Some exemplary scaffolds of the invention
such as in below Example 7 are constructed from scaffold
body components such as fibers which contain, approxi
mately, 40 to 90 wt % BO, 0.1 to 5% CuO, and NaO,
KO, MgO, and POs. More specific examples contain or
even consist essentially of 40 to 90 wt % BO, 0.1 to 5%
CuO, 1 to 25 wt % NaO, 1 to 25 wt % KO, 1 to 25 wt %
MgO, and 1 to 10 wt % POs.
The scaffold component material may be glassy, glass
ceramic, or ceramic in nature. However the glassy state is
preferred in this invention because, generally speaking,
glassy materials are stronger and more chemically homoge
neous than their crystalline or partially crystalline counter
parts of the same composition. It is therefore preferable that
the scaffold body component material is Substantially glass
in that less than about 5 wt %, more preferable less than 1
wt %, of the component material is crystalline material.
More particularly, it is preferable that there is less than 5 wt
%, preferably less than 1 wt %, crystallization when the
material is heated to 800 C at an average heating rate of 20
C/min, held at that temperature for 10 minutes, then cooled
to room temperature by exposure to STP conditions of room
temperature and atmospheric pressure. More preferably, the
glass will contain less than 5 wt % crystallization, even more
preferably less than 1 wt % crystallization, after being
heated to 575 C with a ramp rate of 20 C/min, and held at
that temperature for 20 minutes, then cooled to room tem
perature by exposure to STP conditions.
The scaffold body components of the invention are in the
form of solid fibers, hollow fibers, ribbons, solid spheres,
hollow spheres, particles, and combinations thereof. In an
especially preferred embodiment for many applications, the
scaffold body components include fibers, and in certain Such
embodiments the scaffold body consists essentially of com
ponents which are fibers. The fibers have an aspect ratio of
at least 2:1 length:transverse dimension (e.g., diameter), and
more typically at least 5:1. Such as greater than 10:1. In
certain embodiments of the invention, the scaffold body
components are primarily one form, such as fibers, in
combination with a minor constituent of a second form from
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the foregoing options, such as microspheres.
There is also an option with this invention of employing
distinct component compositions to strategically impart cer
tain properties. For example, the scaffold body employs 10
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crystallization of the glass. Therefore the self-bonding abil
ity of the borate glasses of the invention is a distinct
advantage over other bioactive materials currently in use.

to 90 wt % of components having a composition selected
from the above Tables I and II, and 10 to 90 wt % of

components of a different composition from these Tables. Or
even more than two Such types of components may be
employed. That is, the scaffold may contain at least 10 wt %
of the scaffold body components comprising a first compo
nent material within the contemplated compositions and at
least 10 wt % of scaffold body components comprising a
second component material within the contemplated com
positions, wherein the first and second component materials
have compositions distinct from each other. This permits the
selection of for example, faster reacting fibers in combina
tion with slower reacting fibers; or the selection of Ca
containing fibers with Ca-free fibers; or the selection of trace
element-containing fibers with non-trace-element-contain
ing fibers, to name a few combinations. One can therefore
select standard composition components and combine them
with non-standard composition components to effectively
customize or dope the scaffold for the application presented,
or for the host’s particular needs. Alternatively, hollow
spheres containing a growth factor or drug for delivery to the
host can be incorporated with other structural components,

5

A scaffold of the invention was formed from glass fibers
shown in FIG. 1A, which were about 3 mm long on average
and between about 100 and about 300 microns in diameter.
10

15

between about 30 and about 60 vol%, or between about 60

and about 90%, which are preferred for different applica
tions. Porosity depends on or is controlled by many factors
Such as fiber orientation, shape of particles or microspheres,
and the thermal treatment (time/temperature) used to bond
the elements together. Independent of this bulk porosity,
interconnectivity is also important in the scaffolds of the
invention. Because tissue repair is strongly influenced by
flow of bodily fluids into the scaffold, it is preferred to have
a high level of interconnectivity of pores within the scaffold,
and a low level of closed pores. That is, it is important that
most pores be connected to other pores, and that there is a
director indirect path from most pores to the exterior surface

temperature. The scaffold was then removed from the mold
and is depicted in FIG. 1C.
EXAMPLE 2
25

30

self bonding is evident where two or more rounded shapes
joined. The high degree of interconnectivity of porosity is
also evident from this figure.
35

EXAMPLE 3

A self-bonded borate glass scaffold of the type of
Examples 1 and 2 was implanted Subcutaneously in the back
40

45

sible from the scaffold exterior, and therefore accessible to

bodily fluids.
The method of making the scaffold component materials
is not critical to the invention. By way of example, in
preparing the scaffold component materials, individual ana
lytical reagent grade components are weighed, mixed thor
oughly, and melted in a platinum crucible for approximately
one hour at 1050 C. The melt is then quenched, for example,
on a steel or copper plate to form glass that can be ground
into particulates of a desired size. The particulates can be
spheroidized to form microspheres of a chosen diameter.
The material of preferred composition when in the form of
a melt can easily be formed into fibers. If fibers of the borate
glass are made, they can either be pulled by hand directly
from the melt or pulled through bushing by a rotating drum.
The components can be self bonded to form three dimen
sional scaffolds by simply heating an assemblage of par
ticulates in a furnace and allowing the fibers/particles/
spheres to soften and bond to each other. After the allotted
time at temperature, the construct is removed from the
furnace and cooled to room temperature. Many prior bio
active glasses, such as 45S5, are difficult to self bond due to

A borate based glass fiber scaffold of the invention was
prepared in the manner described in Example 1 and embed
ded in epoxy. A cross section was formed and an optical
photomicrograph was taken and is shown in FIG. 2. The
lighter areas are the epoxy, while darker, rounded shapes are
the glass fibers. They have irregular shapes due to the
random orientation of the fibers in the scaffold. Substantial

of the scaffold. In certain embodiments, at least about 80 vol

%, such as at least about 90%, of the pore volume of the
scaffold is directly or indirectly through other pores acces

The fiber composition was, by wt %, 53 B.O., 6 NaO, 12
KO, 5 MgO, 20 CaO, and 4 POs. The fibers were placed
in the scaffold mold (mullite tube) of FIG. 1B, which was 7
mm in diameter, and enough fiber was placed in the mold
(70 mg) to make a scaffold 2 mm in height. The mold with
fibers randomly oriented therein was placed in a furnace,
with an atmosphere of air and ambient pressure, and heated
for 45 minutes at 575 C. The temperature ramp rate to 575
was about 100 C/min. The scaffold was then removed from
the furnace and the mold allowed to air cool at room

such as fibers.

The scaffold is formed to have a porosity which is selected
to provide fluid flow into the scaffold to facilitate uptake of
bodily fluids, while maintaining sufficient strength for han
dling and implantation. The porosity is between about 15 vol
% and about 90 vol%. There are different levels of porosity,
for example between about 15 and about 30 vol %, or

EXAMPLE 1.

50
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of a rat. After four weeks, the scaffold was removed and

examined by scanning electron microscopy (SEM). A micro
graph was taken (FIGS. 3A and 3B) which revealed soft
tissue Surrounding the fibers. This demonstrates uptake of
physiological fluid into the scaffold and growth of soft tissue
within the scaffold. A hollow core formed in many of the
fibers, as shown, indicating reaction of the glass fibers with
physiological fluids. This is in contrast to the solid nature of
the fibers prior to implantation as shown in FIG. 2. FIGS.
4A, 4B, 4C, and 4D are micrographs at Successively higher
magnifications of one of the fibers from FIGS. 3A and 3B.
The porous reaction layer visible in FIGS. 4C and 4D is
evidence of hydroxyapatite formation. This is confirmed by
the X-ray diffraction analysis of the scaffold shown in FIG.
11, which reveals a pattern consistent with Cao(PO)
(OH).
EXAMPLE 4

A cross section similar to that shown in FIGS. 3A and 3B
60
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having been removed from a rat after four weeks subcuta
neous implantation was Subjected to histological staining
(H&E), and is shown in FIG. 5. This demonstrates biological
compatibility between the tissue and the scaffold, the glass
reaction with the body fluids which formed hollow fibers of
HA and or ACP, and the tissue infiltration throughout the
scaffold and into the hollow voids of the reacted fibers. A

further cross section was taken in a direction parallel to the
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central longitudinal axis of a reacted fiber, and is shown in
FIG. 6. The center of the photomicrograph shows substantial
presence of red blood cells and soft tissue in the sectioned
fiber. FIG. 7 is a further photomicrograph of a cross section
taken in a direction perpendicular to the central axis of a
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TABLE III

Wt. % Composition of Ca-Free Borate Glasses
5

MgO

B2O3

fiber. Red blood cells, blood vessels, and soft tissue can be

I
II

49.3
78.7

III

78.7

IV

76

V
VI

59
45

seen in the hollow core of the reacted glass fiber.

14.6
11.3

BaO

RXn Prods

36.1

BaHPO,
Mg2(PO4)2 +

10

ACP

EXAMPLE 5
10

The immune response of the borate glass of the invention
in comparison to prior art glasses was studied by H&E
staining and examination of cross sections of respective
scaffolds. The sections in FIGS. 8A, 8B, 8C, and 8D were
taken of a scaffold of the invention after two weeks subcu

15

taneous implantation in the back of a rat. These sections
show healthy Soft tissue growing between and attached to
the glass fibers.
There are no giant cells visible close to the fibers. There
are areas with good vascularization, which is important to
the growth of new tissue. Stained sections of a prior art
silicate-based bioactive glass known as 13-93 are shown in
FIGS. 9A, 9B, 9C, and 9D, and almost all the fibers (e.g., F
in 9B) have giant cells attached to and surrounding them.

11.3
11

10

13
33
48

BaHPO.
BaHPO.
Ba(PO4)2

The compounds listed in the right hand column are
reaction products after reacting particles of each glass in a
0.25 molar solution of KHPO at 37 C for 108 to 130 hours.
EXAMPLE 7

Several borate-based glasses were prepared containing
trace amounts of Cu, Sr., Zn, and Fe as oxides in various

amounts according to the following concentrations:
Trace Element Doped Borate Bioactive Glasses (wt %

Glass

The soft tissue penetrating the fibers appears healthy, but the
giant cells Surrounding the fibers are indicative of a foreign
body response. A similar response to the 13-93 glass fibers
occurs for prior art 45S5 glass fibers, as shown in FIGS.
10A, 10B, 10C and 10D. Nearly all the 45S5 fibers are
Surrounded by giant cells indicative of a foreign body
response. The results shown in FIGS. 8A, 8B, 8C, 8D, 9A,

B.O.

Na-O

CaO K-O

MgO

POs CuO SrO ZnO

S3.OO
S2.95
52.89
52.79
52.47
S1.94
S1.73
S120
SO.88

6.OO
S.99
S.99
5.98.
S.94
S.88
S.86
S.80
5.76

20.00
19.98
19.96
19.92
19.8O
19.6O
19.52
19.32
19.2O

S.OO
S.OO
4.99
4.98
495
4.90
4.88
4.83
4.80

4.OO
4.OO
3.99
3.98
3.96
3.92
3.90
3.86
3.84

40
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9B, 9C, 9D, 10A, 10B, 10C and 10D indicate that the

material of invention has no significant immune response
with Soft tissue, and can convert to hydroxyapatite at a much
faster rate than the silicate based bioactive glasses. This
illustrates that the scaffold of the invention, when placed in
contact with tissues containing body fluids, forms a porous
hydroxyapatite material with a hollow core, which can fill
with biological material Such as hard and soft tissue (de
pending on the Surrounding tissues), blood vessels, or pos
sibly other tissues of the body. The histological assessment
after implantation in Subcutaneous soft tissue sites showed a
minimal immune response to the Surrounding and infiltrated
Soft tissue. It also appears to produce a smaller foreign body
response than silicate based bioactive glasses such as 45S5

12.00
11.99
11.98
11.95
11.88
11.76
11.71
11.59
1152

0.10
0.2O
0.40
1.00
2.00
O.40
0.40
040

2.00
2.OO
2.OO

100
100

FeO.

0.40

Scaffolds were prepared from glasses 0, 1, 2, 3, 4, and 5,
which are depicted in FIGS. 12A, 12B, 12C, 12D, 12E, and
12F, respectively. These were implanted subcutaneously in
the backs of rats, and examined for vascularization. FIGS.
13A, 13B, 13C, 13D, 13E, and 13F show the extent of
vascularization after two weeks, and FIGS. 14A, 14B, 14C,

14D, 14E, and 14F after four weeks, for glasses 0 through
5, respectively. The effect of increasing Cu content on
increasing vascularization is evident.
EXAMPLE 8

50

A blended fiber scaffold was prepared from a 50:50 by
weight mixture of fibers of two distinct compositions:
55

Glass
Fiber

60

Content

B.O.

NaO

CaO

K-O

MgO

POs

CuO

50%
50%

53.00
52.47

6.OO
5.94

2O.OO
1980

12.OO
11.88

SOO
495

4.OO
3.96

1.OO

and 13-93.
EXAMPLE 9

EXAMPLE 6

In-vitro experiments were conducted to measure the reac
tion rates and the reaction products of the following Ca-free
borate-based glasses (compositions in weight 96):

65

The dissolution of boric acid in vivo is calculated. With a

53 wt % B.O. glass and an exemplary scaffold mass of 0.070
g, the weight of BO is 0.0371 g. The BO dissolves into

US 9,561,250 B2
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13
the bodily fluids and is present as BO ions. For purpose of
comparison to literature values, however, calculation here is
made on the basis of HBO. The gravimetric factor of BO
to HBO is 1.78, so the 0.0371 g of BO dissolves into

-continued
SiO2
Al2O3
F
transition metal elements

0.066 g HBO, which corresponds to 1.07E moles

HBO. It was assumed, based on in vivo observations, that
it takes four weeks for a B.O. based scaffold of this size to

completely react. This corresponds to 1.07E/28
days=3.814E moles/day HBO, yield. Prior observations
also show that roughly 0.05 g of new tissue weight grows

10

and about 50 wt %,
15

2. The scaffold of claim 1 wherein the BO concentration

mM HBO. Then assuming the maximum flow, the HBO
yield is calculated to have a concentration of 1.32 mM: 1440

is between about 50 and about 90 wt %.

3. The scaffold of claim 1 wherein the BO, concentration

min/day (0.4 ml/min/gram)=28.8 ml=0.0288 L. 3.814E
moles/day HBO/0.0288 L=1.32E mol/L=1.32 mM

is between about 60 and about 82 wt %.
4. The scaffold of claim 1 wherein:
25

lative concentration between 5 and 25 wt % and two or

a cumulative concentration between 1 and 45 wt %; and
30

When introducing elements of the present invention or the
preferred embodiments(s) thereof, the articles “a”, “an',

5. The scaffold of claim 1 wherein the scaffold body
components contain MgO in a concentration is between

“the' and “said are intended to mean that there are one or

about 1 and 25 wt %.
35

elements.
40

above description and shown in the accompanying drawings
shall be interpreted as illustrative and not in a limiting sense.

40 to
O to
O to
O to
O to

90
25
25
25
25

CaO

O to 40

MgO

O to 25

SO
BaO

O to 40
O to SO

POs

O to 10

7. The scaffold of claim 1 wherein the component material
comprises two or more oxides from among LiO, NaO.
KO, and RbC) in a cumulative concentration between 5 and
25 wt %.

The invention claimed is:

B2O3
Na2O
Li2O
KO
Rb2O

6. The scaffold of claim 1 wherein the scaffold body
components contain KO in a concentration is between
about 1 and 25 wt % and MgO in a concentration is between
about 1 and 25 wt %.

invention, it is intended that all matter contained in the

1. A three-dimensional scaffold with interconnected pores
for repair of tissue comprising:
a scaffold body for structural support of the tissue scaffold
comprising:
scaffold body components bonded to each other to define
the scaffold body and provide a scaffold body com
pressive strength of greater than 5 MPa, wherein the
Scaffold body components are components in the form
of fibers in combination with one or more components
in the form of ribbons, solid spheres, hollow spheres,
and particles, and the components are of a component
material comprising, by approximate weight 96:

less than 5 wt % of the component material is crystalline
material.

results attained.

As various changes could be made in the above compo
sitions and methods without departing from the scope of the

the BO concentration is between 50 and 90 wt %;
the component material comprises two or more oxides
from among Li2O, NaO, KO, and RbC) in a cumu
more oxides from among MgO, SrO, BaO, and CaO in

In view of the above, it will be seen that the several

more of the elements. The terms “comprising”, “including
and “having” are intended to be inclusive and mean that
there may be additional elements other than the listed

wherein the scaffold body has a porosity between about 15
and about 90 vol%.

3.814E moles/day HBO/0.0072 L=5.29E mol/L=5.29

objects of the invention are achieved and other advantageous

wherein two or more of LiO, Na2O, K2O, and Rb-O are
present in a cumulative concentration between about 1
wherein two or more of MgO, SrO, BaO, and CaO are
present in a cumulative concentration between about 1

day (0.1 ml/ming)(1 day) (0.05 g)=7.2 ml=0.0072 L.

HBO. Based on data available in “Action of Boron at the
Molecular Level, Bio. Trace Ele. Res., 85, 2002, HBO, in
this concentration may stimulate RNA uptake. Accordingly,
in sharp contrast to silicate-based scaffolds, the scaffolds of
the invention upon dissolution naturally yield a Substance
which has been reported to function as a growth factor to
enhance healing.

O to 4
O to 10
cumulative

and about 50 wt %,

into a scaffold of this size. Prior observations also show that

roughly between about 0.1 (minimum) and about 0.4 (maxi
mum) ml/min of blood flows through a scaffold per gram of
tissue. First assuming the minimum flow, the HBO, yield is
calculated to have a concentration of 5.29 mM: 1440 min/

O to 18
O to 3

45

8. The scaffold of claim 1 wherein the component material
comprises two or more oxides from among LiO, NaO.
KO, and RbC) in a cumulative concentration between 5 and
25 wt % and two or more oxides from among MgO, SrO.
BaO, and CaO in a cumulative concentration between 1 and
45 wt %.

50
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9. The scaffold of claim 1 wherein the component material
further comprises one or more elements selected from the
group consisting of Zn, Cu, Fe, Mn, Si, Sr., Ni, Mo, and Se,
in an amount between about 0.01 and 10 wt % per element
and cumulatively less than 25 wt %.
10. The scaffold of claim 1 wherein the component
material further comprises between about 0.01 and 10 wt %
Cu as copper oxide.
11. A three-dimensional scaffold with interconnected

60
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pores for repair of tissue comprising:
a scaffold body for structural support of the tissue scaffold
comprising:
scaffold body components bonded to each other to define
the scaffold body and provide a scaffold body com
pressive strength of greater than 0.4 MPa, wherein the
Scaffold body components are of a component material
comprising, by approximate weight 96:

US 9,561,250 B2
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B2O3
NaO
Li2O
KO
Rb2O

40 to
O to
O to
O to
O to

90
25
25
25
25

CaO

O to 40

MgO

O to 25

SO
BaO

O to 40
O to SO

POs
SiO2
Al2O3

O to 10
O to 18
O to 3

F
transition metal elements

16
14. The scaffold of claim 1 wherein the body components
comprise the glass fibers and the particles.
15. The scaffold of claim 1 wherein the scaffold body
consists essentially of the glass fibers and the one or more
components in the form of ribbons, solid spheres, hollow
spheres, and particles.
16. The scaffold of claim 1 wherein the scaffold body
components consist essentially of 40 to 90 wt % BO, 1 to
10

O to 4
O to 10
cumulative

wherein two or more of LiO, NaO, K2O, and RbC) are
present in a cumulative concentration between about 1

15

and about 50 wt %, 0

wherein two or more of MgO, SrO, BaO, and CaO are
present in a cumulative concentration between about 1
and about 50 wt %,

wherein the scaffold body has a porosity between about 15
and about 90 vol%, and

wherein at least 10 wt % of the scaffold body components
have a first composition and at least 10 wt % of the
Scaffold body components have a second composition,
wherein the first and second compositions are distinct

ticles.
25

from each other.
12. The scaffold of claim 1 wherein less than 5 wt % of

the component material is crystalline material.
13. The scaffold of claim 1 wherein the component
material, upon exposure to natural or simulated physiologi
cal phosphorus-containing fluids, does not react to form a
crystalline or amorphous calcium phosphate.

25 wt % NaO, 1 to 25% K2O, 1 to 40 wt % CaO, 1 to 25
wt % MgO, and 1 to 10 wt % P.O.
17. The scaffold of claim 1 wherein the scaffold body
components consist essentially of 40 to 90 wt % BO, 1 to
25 wt % LiO, and 1 to 40 wt % CaO.
18. The scaffold of claim 1 wherein the scaffold body
components consist essentially of 40 to 90 wt % BO, 1 to
25 wt % NaO, and 1 to 40 wt % CaO.
19. The scaffold of claim 1 wherein the scaffold body
components consist essentially of 40 to 90 wt % BO, 0.1
to 5% CuO, 1 to 25 wt % NaO, 1 to 25 wt % K2O, 1 to 25
wt % MgO, and 1 to 10 wt % P.O.
20. The scaffold of claim 1 wherein the scaffold body
components consist essentially of the fibers and the par

21. The scaffold of claim 1 wherein the scaffold body
components comprise the fibers and the solid spheres.
22. The scaffold of claim 1 wherein the compressive
strength of the scaffold body is greater than 5 MPa and no
more than 200 MPa.

30

23. The scaffold of claim 22 wherein the compressive
strength of the scaffold body is between 20 and 200 MPa.
k
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